The economics of reproducibility in preclinical research

Thumbnail
License
Copyright: © 2015 Freedman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Date Issued
2015-06-01
Publisher Version
10.1371/journal.pbio.1002165
Author(s)
Freedman, Leonard P.
Cockburn, Iain M.
Simcoe, Timothy S.
Share to FacebookShare to TwitterShare by Email
Export Citation
Metadata
Show full item record
Permanent Link
https://hdl.handle.net/2144/40268
Version
Published version
Citation (published version)
Leonard P Freedman, Iain M Cockburn, Timothy S Simcoe. 2015. "The Economics of Reproducibility in Preclinical Research." PLoS Biology, Volume 13, Issue 6, 9 pp. https://doi.org/10.1371/journal.pbio.1002165
Abstract
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible—in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.
Rights
Copyright: © 2015 Freedman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Collections